Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

31.68

-0.14 (0.44%)

as of Jul 15, 2026, 6:03:36 pm Market Open.

69 watching

Investor Insights

Jul 15, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Teva Pharmaceutical (TEVA-N) is experiencing a significant turnaround under its current CEO, with a remarkable 264% increase since January 2023. The demand for GLP (glucagon-like peptides) remains strong; however, the entry of more generics into the market could lead to declining prices. While analysts highlight the potential for innovation, concerns remain about Teva's lack of innovative capabilities. The stock has shown strong momentum, breaking out over $21 in September and maintaining positive accumulation trends for the past six months. Despite not offering dividends, analysts have set a price target of $34.50 for the stock, indicating further potential growth amidst favorable market conditions for drug stocks.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer,PFE

COMMENT

Likes the generic drug space, especially with the new US administration. There are a lot of moves up in estimates, both quarterly and annual. He also likes Mylan (MYL-Q), which has a little bit more growth and probably cheaper on a PE level.

DON'T BUY

Once generic stocks have their products in place they can milk it for several years to come. He wouldn't be looking at this right now.

PAST TOP PICK

(A Top Pick July 21/08. Up 14.55%.)

TOP PICK

Has 25% of the US generic drug market. Generics will gain with the government’s new health plans. Trades at about 15X earnings. Long record of successfully increasing earnings and dividends.

BUY

Largest generic drug manufacturer globally. Grows through patents coming off existing drugs and by making acquisitions. Have also developed a number of drugs on their own.

TOP PICK

Countries everywhere will be looking at ways of cutting back on drug costs. This is the biggest generic drug company globally. A defensive sector.

TOP PICK

During the bear market decline, this stock held in like a rock. It's both defensive and growth. Selling at less than half of its 30% growth rate. Hitting on all cylinders.

TOP PICK

World's largest drug market and will benefit from US push to lower health care costs. Likes it for growth. Likely to see 30% in short term. Biggest risk is the development of new drug candidates.

TOP PICK

World’s largest generic manufacturer. With their Barr acquisition they now have 25% of the US generic market and 17% of the total prescription market. This is in an era where it looks like the US administration is moving to a more nationalized health care plan

TOP PICK

Worlds largest maker of generic drugs. US administration is likely to push forward towards greater use of generics that would give them a $9.2 billion savings over the next 10 years. This company will be a beneficiary. Made an acquisition last year of Barr Pharmaceuticals, which will give them good synergies.

TOP PICK

Israeli-based pharmaceutical company. Recently completed an acquisition of US Barr Pharmaceuticals giving them the largest share (25%) of the generic market in the US. US healthcare focus on generics is going to increase. Leader in producing new generics and is able to negotiate better prices for its products. Earnings in 2010 are expected to increase by more than 30%. Small but growing dividend.

PAST TOP PICK

(A Top Pick Feb 26/02. Down 10.2%.)

TOP PICK

Generic drugs. Manufactures more than 25% of the US market. In a move to more universal medicine in the US, generic manufacturers are going to be big beneficiaries. Earnings are likely to increase by 50% in the 2009 to 2012 period. Trading at 15X earnings.

COMMENT

(Market Call Minute.) Likes this as a company. In the very short run the health care stocks are under performing in the last couple of weeks. If you like pharmaceuticals, this is one that you could purchase.

DON'T BUY

Outsource pharmaceutical manufacturer of generic drugs. No barriers to stop others from doing the same kind of business. He prefers Johnson & Johnson (JNJ-N) or Novartis (NVS-N) who specialize in what they do.

Showing 196 to 210 of 276 entries

Most Recent Experts

Colin Cieszynski

SIA Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)